Stromal–Epithelial Crosstalk Provides a Suitable Microenvironment for the Progression of Ovarian Cancer Cells in Vitro

REFERENCES

• Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61: 183–203.
   PubMed Web of Science ®Google Scholar
• Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011;223: 162–176.
   PubMedGoogle Scholar
• Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci 2012;125:5591–5596.
   PubMed Web of Science ®Google Scholar
• McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013;12:217–228.
   PubMed Web of Science ®Google Scholar
• Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324–1331.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436–444.
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359–1370.
   PubMed Web of Science ®Google Scholar
• Polanska UM, Orimo A. Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013;228:1651–1657.
   PubMed Web of Science ®Google Scholar
• Viola A, Sarukhan A, Bronte V, Molon B. The pros and cons of chemokines in tumor immunology. Trends Immunol 2012;33:496–504.
   PubMed Web of Science ®Google Scholar
• Seton-Rogers S. Cytokine cues. Nat Rev Cancer 2011;11:690.
   PubMedGoogle Scholar
• Mukaida N, Baba T. Chemokines in tumor development and progression. Ex Cell Res 2012;318:95–102.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392–401.
   PubMed Web of Science ®Google Scholar
• Hu C, Wang Z, Zhai L, Yang M, Shan L, Chai C, Liu M, Wang L. Effects of cancer-associated fibroblasts on the migration and invasion abilities of SGC-7901 gastric cancer cells. Oncol Lett 2013;5:609–612.
   PubMed Web of Science ®Google Scholar
• Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2012;31:195–208.
   PubMed Web of Science ®Google Scholar
• Liu M, Xu J, Deng H. Tangled fibroblasts in tumor-stroma interactions. Int J Cancer 2011;129:1798–1805.
   Google Scholar
• Brentnall TA, Lai LA, Coleman J, Bronner MP, Pan S, Chen R. Arousal of cancer-associated stroma: overexpression of palladin activates fibroblasts to promote tumor invasion. PLoS One 2012;7:e30219.
   Google Scholar
• Zhang Y, Tang H, Cai J, Zhang T, Guo J, Feng D, Wang Z. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett 2011;303:47–55.
   PubMed Web of Science ®Google Scholar
• Cai J, Tang H, Xu L, Wang X, Yang C, Ruan S, Guo J, Hu S, Wang Z. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 2012;33:20–29.
   PubMed Web of Science ®Google Scholar
• Zhang C, Fu L, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX, Guan XY. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res 2009;15:4017–4027.
   PubMed Web of Science ®Google Scholar
• Huang R, Jiang W, Yang J, Mao YQ, Zhang Y, Yang W, Yang D, Burkholder B, Huang RF, Huang RP. A biotin label-based antibody array for high-content profiling of protein expression. Cancer Genomics Proteomics 2010;7:129–141.
   PubMedGoogle Scholar
• Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012;72:2473–2480
   PubMed Web of Science ®Google Scholar
• Finley SD, Popel AS. Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions. J Natl Cancer Inst 2013;105:802–811.
   PubMed Web of Science ®Google Scholar
• Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. TGF-beta signalling in colon carcinogenesis. Cancer Lett 2012;314:1–7.
   PubMedGoogle Scholar
• Taylor MA, Lee YH, Schiemann WP. Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr 2011;15:117–132.
   PubMed Web of Science ®Google Scholar
• Steffan JJ, Coleman DT, Cardelli JA. The HGF-met signaling axis: emerging themes and targets of inhibition. Curr Protein Pept Sci 2011;12:12–22.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141: 52–67.
   PubMed Web of Science ®Google Scholar
• Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, Angel P, Mueller MM. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 2010;31:1175–1184.
   PubMed Web of Science ®Google Scholar
• Eiró N, González L, González LO, Fernandez-Garcia B, Lamelas ML, Marín L, González-Reyes S, del Casar JM, Vizoso FJ. Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS One 2012;7:e49047.
   Google Scholar
• Liu Y, Li Y, Liu Z, Zhang L, Anniko M, Duan M. Prognostic significance of matrix metalloproteinase-20 overexpression in laryngeal squamous cell carcinoma. Acta Otolaryngol 2011;131:769–773.
   PubMed Web of Science ®Google Scholar
• Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol 2013;33:S79–S84.
   PubMed Web of Science ®Google Scholar
• Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012;32:1119–1136.
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359–1370.
   PubMed Web of Science ®Google Scholar
• Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM, Womack C: Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010;16: 3548–3561.
   PubMed Web of Science ®Google Scholar
• Brunckhorst MK, Wang H, Lu R, Yu Q. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res 2010;70:7283–7293.
   PubMed Web of Science ®Google Scholar
• Grootaert C, Van de Wiele T, Verstraete W, Bracke M, Vanhoecke B. Angiopoietin-like protein 4: health effects, modulating agents and structure-function relationships. Expert Rev Proteomics 2012;9:181–199.
   PubMed Web of Science ®Google Scholar
• Singh H, Tahir TA, Alawo DO, Issa E, Brindle NP. Molecular control of angiopoietin signalling. Biochem Soc Trans 2011;39: 1592–1596.
   PubMed Web of Science ®Google Scholar
• Deepak P, Kumar S Jr, Kishore D, Acharya A. IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma. Int Immunol 2010;22:53–63.
   PubMed Web of Science ®Google Scholar
• Stagg HW, Bowen KA, Sawant DA, Rodriguez M, Tharakan B, Childs EW. Tumor necrosis factor-related apoptosis-inducing ligand promotes microvascular endothelial cell hyperpermeability through phosphatidylinositol 3-kinase pathway. Am J Surg 2013;205:419–425.
   PubMed Web of Science ®Google Scholar
• Rodrigues-Lisoni FC, Peitl P Jr, Vidotto A, Polachini GM, Maniglia JV, Carmona-Raphe J, Cunha BR, Henrique T, Souza CF, Teixeira RA, Fukuyama EE, Michaluart P Jr, de Carvalho MB, Oliani SM; Head and Neck Genome Project GENCAPO, Tajara EH, Cury PM, de Carvalho MB, Dias-Neto E, Figueiredo DL, Fukuyama EE, Góis-Filho JF, Leopoldino AM, Mamede RC, Michaluart-Junior P, Moyses RA, Nóbrega FG, Nóbrega MP, Nunes FD, Ojopi EF, Serafini LN, Severino P, Silva AM, Silva WA Jr, Silveira NJ, Souza SC, Tajara EH, Wünsch-Filho V, Amar A, Bandeira CM, Braconi MA, Brandão LG, Brandão RM, Canto AL, Cerione M, Cicco R, Chagas MJ, Chedid H, Costa A, Cunha BR, Curioni OA, Fortes CS, Franzi SA, Frizzera AP, Gazito D, Guimarães PE, Kaneto CM, López RV, Macarenco R, Magalhães MR, Meneses C, Mercante AM, Pinheiro DG, Polachini GM, Rapoport A, Rodini CO, Rodrigues-Lisoni FC, Rodrigues RV, Rossi L, Santos AR, Santos M, Settani F, Silva FA, Silva IT, Souza TB, Stabenow E, Takamori JT, Valentim PJ, Vidotto A, Xavier FC, Yamagushi F, Cominato ML, Correa PM, Mendes GS, Paiva R, Ramos O, Silva C, Silva MJ, Tarl´ MV. Genomics and proteomics approaches to the study of cancer-stroma interactions. BMC Med Genomics 2010;3:14.
   PubMed Web of Science ®Google Scholar